Lots of interesting abstracts and cases were submitted for TCTAP 2025. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-005
Early Outcomes With Three TAVI Valves in Women - Insight of LANDMARK Trial
By
Presenter
Authors
1
Affiliation
, 1
View Study Report
TCTAP A-005
Minimalist TAVR
Early Outcomes With Three TAVI Valves in Women - Insight of LANDMARK Trial
1
, 1
Background
Nearly 50% of severe aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR) are women, yet they are under-represented in clinical trials. SMART trial reported that in women with small annulus area, self-expanding transcatheter heart valve (THV) showed better hemodynamic outcomes than balloon-expandable THV. In the LANDMARK trial comparing three types of THVs, outcomes in women were investigated.
Methods
In a multicenter, non-inferiority LANDMARK trial (n=768), 369 women with severe AS were randomized to Myval THV series(n=193), Sapien THV series (n=86), and Evolut THV series (n=90). The primary endpoint at 30 days was a composite of all-cause death, all stroke, bleeding (types 3 and 4), acute kidney injury (stages 2-4), major vascular complications, moderate or severe prosthetic valve regurgitation (PVR), and new permanent pacemaker implantation as per the Valve Academic Research Consortium-3 consensus.
Results
The results and conclusions of the BEST CLINICAL ABSTRACTS will be released after the presentation on April 25.
Conclusion
The results and conclusions of the BEST CLINICAL ABSTRACTS will be released after the presentation on April 25.